Disc Medicine's Q3 net loss narrows on lower R&D expenses
IRON•Disc Medicine reported a Q3 net loss of $59.54 million, or $1.53 per share, compared with analyst estimates of $68.54 million and $1.73 per share. The company plans a bitopertin NDA resubmission by the end of 2026 and expects its cash to fund operations and obligations into 2030.
1. Quarterly results
Disc Medicine's Q3 net loss and loss per share narrowed year over year. Net loss was $59.54 million, or $1.53 per basic share, while operating loss was $64.16 million; analyst estimates were $68.54 million, $1.73 per share and $72.41 million, respectively. Lower research and development expenses contributed to the results, reflecting the absence of a prior-year milestone payment and drug manufacturing costs.
2. Pipeline and cash
The company plans to resubmit the bitopertin NDA by the end of 2026, with an FDA decision expected by mid-2027. It plans to announce pivotal development plans for selcodebart in anemia of myelofibrosis by year-end and expects its cash position to fund operations and obligations into 2030.
